NCT05860881View on ClinicalTrials.gov

Topical Sirolimus in Chemoprevention of Facial Squamous Cell Carcinomas in Solid Organ Transplant Recipients (SiroSkin)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

146

Participants

Timeline

Start Date

February 9, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Solid Organ Transplant RecipientsSkin Cancer
Interventions
DRUG

Sirolimus Topical Cream

The intervention topical cream consists of sirolimus 1% in a vehicle. Patients randomised to the intervention will be required to apply the sirolimus topical cream to their face for 6 months

OTHER

Placebo

Cream containing only the base, or vehicle.

Trial Locations (6)

2050

Royal Prince Alfred Hospital, Camperdown

2145

Westmead Hospital, Westmead

3004

The Alfred Hospital, Melbourne

3053

Skin Health Institute, Carlton

4032

The Prince Charles Hospital, Chermside

4102

Princess Alexandra Hospital, Woolloongabba

All Listed Sponsors
collaborator

Monash University

OTHER

collaborator

The University of Queensland

OTHER

lead

Melanoma and Skin Cancer Trials Limited

OTHER

NCT05860881 - Topical Sirolimus in Chemoprevention of Facial Squamous Cell Carcinomas in Solid Organ Transplant Recipients (SiroSkin) | Biotech Hunter | Biotech Hunter